As per the latest report by IMARC Group, titled “Europe Dry Eye Syndrome Market Report by Disease Type (Evaporative Dry Eye Syndrome, Aqueous Dry Eye Syndrome), Drug Type (Anti-inflammatory Drugs, Lubricant Eye Drops, Autologous Serum Eye Drops), Product (Liquid Drops, Gel, Liquid Wipes, Eye Ointment, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Country 2024-2032,” the Europe dry eye syndrome market size reached US$ 757.2 Million in 2023. Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a medical condition that occurs due to the lack of moisture or lubrication on the surface of the eye. It is characterized by symptoms, including irritation, redness, discharge, fatigued eyes, and blurred vision. It is caused by various reasons such as hormone changes, autoimmune disease, inflamed eyelid glands, allergic eye disease, extensive computer usage, and medication that disrupt the healthy tear film. However, dry eye syndromecan be treated through administering artificial tears, medications, lacrimal plugs, and surgeries.
Europe Dry Eye Syndrome Market Trends:
The rising geriatric population, which is more susceptible to chronic eye diseases, is one of the key factors driving the market growth. Dry eye syndrome is also caused by various other medical conditions, such as Sjogren’s syndrome, lupus, scleroderma, rheumatoid arthritis, sarcoidosis, thyroid disorders, and diabetes, which is highly prevalent among elderly patients. In addition, sedentary lifestyles and a lack of physical activities of the masses are leading to increased oxidative stress and reduced mucin expression in the eyes. As a result, patients and healthcare providers are widely adopting corticosteroid drugs to effectively treat dry eye syndrome,. Furthermore, the improving diagnostic technologies, rising healthcare expenditure capacities of consumers, and increasing utilization of smartphones, laptops and television among the masses leading to prolonged and excessive screen time are some of the other factors creating a positive market outlook across the region. Looking forward, IMARC Group expects the market value to reach US$ 1,153.5 Million by 2032, exhibiting a CAGR of 4.6% during the forecast period (2024-2032).
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Million |
Segment Coverage | Disease Type, Drug Type, Product, Distribution Channel, Country |
Countries Covered | Germany, France, United Kingdom, Italy, Spain |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800